{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-24-000879","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.936912+00:00","generated_at":"2026-06-05T00:33:25.891442+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entera Bio FY2023 net loss narrows to $8.9M; cash runway into Q2 2025; five oral peptide programs on track","bullets":["Net loss for FY2023 was $8.9M ($0.31/share), down from $13.1M ($0.45/share) in FY2022.","Cash and cash equivalents $11.0M as of Dec 31, 2023; sufficient to fund operations through Q2 2025.","R&D expenses decreased to $4.5M from $5.8M; G&A decreased to $4.4M from $7.3M due to cost cuts.","Key 2024 milestones: Phase 1 PK data for EB612 (H1), pre-IND PK for GLP-2 (H1) and OXM (mid-2024), SABRE update.","Advancing five oral peptide programs: EB613 (osteoporosis), EB612 (hypoparathyroidism), GLP-2, OXM, stress fractures."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-24-000879","json":"https://secwatch.observer/filing/0001178913-24-000879.json","markdown":"https://secwatch.observer/filing/0001178913-24-000879.md","text":"https://secwatch.observer/filing/0001178913-24-000879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/0001178913-24-000879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/zk2431116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:33:25.891442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07fcf013e8a5eb3204c084877fd08aab2a496744","claim":"Entera Bio Ltd. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On March 8 , 2024, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/0001178913-24-000879-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}